- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
RYE, N.Y. — A drug in late-stage clinical trials appears to treat the symptoms of autism, the drug's developer said Wednesday.
Curemark announced results of the phase-3 trial of CM-AT in children ages 3 to 8 years. The company said the drug had a statistically significant effect on symptoms of autism compared with placebo. The Food and Drug Administration has granted the drug fast-track status, which it does for investigational drugs to treat serious or life-threatening conditions that may address unmet medical needs.
"We are extremely pleased with the results of our trial," Curemark CEO Joan Fallon said. "We wish to thank all the children and their parents who participated in the study and look forward to a full review of the data by the FDA."